NexTel Medical signs letter of intent to acquire Xycota Biosciences and expand into neuroplasticity therapeutics

The proposed acquisition would add Xycota’s preclinical CNS pipeline and exosome-based delivery platform to NexTel Medical, including lead programme XYCO-01 for frontotemporal dementia.

NexTel Medical Corp. has signed a letter of intent to acquire 100% of Xycota Biosciences, an early-stage biotechnology company developing exosome-delivered neuroplasticity therapeutics for neurodegenerative conditions.

If completed, the transaction would give NexTel access to Xycota’s preclinical pipeline and delivery technology, led by XYCO-01, an exosome-formulated psilocin candidate being developed initially for frontotemporal dementia (FTD).

Field	Content
Alert Type	Deal
Companies	NexTel Medical Corp.; Xycota Biosciences
Deal Type	Proposed acquisition under letter of intent
Asset or Company	100% of Xycota Biosciences, including its neuroplasticity therapeutic pipeline and exosome delivery platform
Therapy Area(s)	Neurology; Neurodegenerative diseases
Technology or Modality	Exosome-delivered neuroplasticity therapeutics
Deal Value	Financial consideration for the proposed acquisition has not been disclosed.
Development Stage	Preclinical
Geography	United States
What Happened	NexTel Medical Corp. announced that it has executed a letter of intent to acquire 100% of Xycota Biosciences. The proposed transaction would give NexTel ownership of Xycota’s CNS drug-development platform and preclinical programmes. Xycota’s lead asset, XYCO-01, is an exosome-formulated psilocin candidate initially targeting FTD, with additional programmes or potential applications in mild traumatic brain injury, ALS and other neurodegenerative conditions. The announcement represents a proposed transaction rather than a completed acquisition, and completion remains dependent on definitive documentation and other agreed conditions. (Xycota Biosciences)
Why It Matters	The proposed acquisition would extend NexTel’s biotechnology portfolio into CNS drug development and give it access to a differentiated approach combining neuroplasticity pharmacology with exosome-based delivery. Xycota is attempting to exploit the BDNF-TrkB neuroplasticity pathway while reducing or avoiding the hallucinogenic effects associated with conventional psychedelic administration, but these delivery and therapeutic hypotheses remain to be validated clinically. (Xycota Biosciences)
Supporting Context	Xycota describes XYCO-01 as an exosome-formulated psilocin programme intended initially for FTD. Its strategy is supported by preclinical research investigating the role of BDNF-TrkB signalling in psilocybin-associated neuroplasticity, but Xycota states that its programmes remain preclinical and that clinical trials have not begun. (Xycota Biosciences)
Strategic Rationale	NexTel would gain ownership of an early-stage CNS platform and pipeline that could broaden its biotechnology activities into neurodegeneration. For Xycota, the proposed transaction could provide access to NexTel’s public-company infrastructure and resources as its lead programme moves towards regulatory and clinical development.
Potential Impact	If completed and successfully developed, the acquisition could give NexTel a platform spanning several neurodegenerative indications. Any clinical or commercial impact remains highly uncertain because the programmes are preclinical and their safety and efficacy have not been established in patients. (Xycota Biosciences)
Key Takeaway	The proposed acquisition would give NexTel ownership of Xycota’s preclinical neuroplasticity platform, but its strategic value will depend on completion of the transaction and subsequent clinical validation.
What to Watch	Execution of a definitive acquisition agreement, disclosure of the transaction consideration and closing conditions, and Xycota’s progress towards regulatory clearance and first-in-human development of XYCO-01.
Primary Source	Morningstar/Accesswire announcement supplied: https://www.morningstar.com/news/accesswire/1201772msn/nextel-medical-corp-executes-letter-of-intent-to-acquire-100-of-xycota-biosciences-llc
Relevant Date	August 2026

---

Discover how nuaxia can support your next medical education initiative:

• Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector 

• Contact us on: support@nuaxia.com